172 related articles for article (PubMed ID: 38240948)
1. Burden of Illness of Type 2 Diabetes Mellitus in the Kingdom of Saudi Arabia: A Five-Year Longitudinal Study.
AlHarbi M; Othman A; Nahari AA; Al-Jedai AH; Cuadras D; Almalky F; AlAzmi F; Almudaiheem HY; AlShubrumi H; AlSwat H; AlSahafi H; Sindi K; Basaikh K; AlQahtani M; Lamotte M; Yahia M; Hassan ME; AlMutlaq M; AlRoaly M; AlZelaye S; AlGhamdi Z
Adv Ther; 2024 Mar; 41(3):1120-1150. PubMed ID: 38240948
[TBL] [Abstract][Full Text] [Related]
2. The humanistic and economic burden of atopic dermatitis among adults and adolescents in Saudi Arabia.
Elezbawy B; Fasseeh AN; Fouly E; Esba LCA; Al Abdulkarim H; Al-Haddab M; Al-Sheikh A; Altawil E; Al Turaiki A; Eshmawi M; Hamadah I; Tannira M; Dalle H; Aderian S; Roshdy A; Jaheen A; Hamad T; Abaza S; Kaló Z
J Med Econ; 2022; 25(1):1231-1239. PubMed ID: 36426726
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal assessment of the quality of life and patterns of antidiabetic medication use in patients with type 2 diabetes, Saudi Arabia perspective, DISCOVER study.
Al-Rubeaan K; Banah F; Alruwaily FG; Sheshah E; Alnaqeb D; AlQahtani AM; Ewais D; Al Juhani N; Hassan AH; Youssef AM
Curr Med Res Opin; 2023 Jan; 39(1):27-35. PubMed ID: 36342972
[TBL] [Abstract][Full Text] [Related]
4. Cost of cardiovascular diseases and renal complications in people with type 2 diabetes mellitus in the Kingdom of Saudi Arabia: A retrospective analysis of claims database.
Al-Jedai AH; Almudaiheem HY; Alissa DA; Al-Enazy HS; Korayem GB; Alghamdi A; Alghamdi S
PLoS One; 2022; 17(10):e0273836. PubMed ID: 36264903
[TBL] [Abstract][Full Text] [Related]
5. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
6. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
7. Therapy conversion to biphasic insulin aspart 30 improves long-term outcomes and reduces the costs of type 2 diabetes in Saudi Arabia.
Ali M; White J; Lee CH; Palmer JL; Smith-Palmer J; Fakhoury W; Valentine WJ
J Med Econ; 2008; 11(4):651-70. PubMed ID: 19450074
[TBL] [Abstract][Full Text] [Related]
8. Budget impact of introducing oral semaglutide to the public healthcare benefit package in Saudi Arabia.
Alluhidan M; Alabdulkarim H; Alrumaih A; Al-Turaiki A; Alshahrani A; Al-Qahtani S; Alhossan A; Al-Jedai A
J Med Econ; 2023; 26(1):1455-1468. PubMed ID: 37933169
[TBL] [Abstract][Full Text] [Related]
9. An analysis of the cost-effectiveness of switching from biphasic human insulin 30, insulin glargine, or neutral protamine Hagedorn to biphasic insulin aspart 30 in people with type 2 diabetes.
Gupta V; Baabbad R; Hammerby E; Nikolajsen A; Shafie AA
J Med Econ; 2015 Apr; 18(4):263-72. PubMed ID: 25426701
[TBL] [Abstract][Full Text] [Related]
10. Review of models used in economic analyses of new oral treatments for type 2 diabetes mellitus.
Asche CV; Hippler SE; Eurich DT
Pharmacoeconomics; 2014 Jan; 32(1):15-27. PubMed ID: 24357160
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of upadacitinib as a treatment option for patients with rheumatoid arthritis in the Kingdom of Saudi Arabia.
Al-Abdulkarim H; Sharma Y; Attar SM; Husain W; Al-Homood I; Al Omari B; Mohamed O; Alsaqa'aby M; Jaheen AM; Anwar A; Hamad TM; Alzahrani Z
J Med Econ; 2024; 27(1):134-144. PubMed ID: 38163926
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis.
Tunis SL; Minshall ME; Conner C; McCormick JI; Kapor J; Yale JF; Groleau D
Curr Med Res Opin; 2009 May; 25(5):1273-84. PubMed ID: 19366302
[TBL] [Abstract][Full Text] [Related]
13. Safety, effectiveness, and cost of dipeptidyl peptidase-4 inhibitors versus intermediate acting insulin for type 2 diabetes: protocol for a systematic review and network meta-analysis.
Tricco AC; Antony J; Soobiah C; Hemmelgarn B; Moher D; Hutton B; Yu CH; Majumdar SR; Straus SE
Syst Rev; 2013 Jun; 2():47. PubMed ID: 23810103
[TBL] [Abstract][Full Text] [Related]
14. Demographic and Clinical Profiles of Type 2 Diabetes Mellitus Patients Initiating Canagliflozin Versus DPP-4 Inhibitors in a Large U.S. Managed Care Population.
Grabner M; Peng X; Geremakis C; Bae J
J Manag Care Spec Pharm; 2015 Dec; 21(12):1204-12. PubMed ID: 26679969
[TBL] [Abstract][Full Text] [Related]
15. Lifestyle related risk factors of type 2 diabetes mellitus in Saudi Arabia.
Midhet FM; Al-Mohaimeed AA; Sharaf FK
Saudi Med J; 2010 Jul; 31(7):768-74. PubMed ID: 20635010
[TBL] [Abstract][Full Text] [Related]
16. Ambient particulate matter burden of disease in the Kingdom of Saudi Arabia.
Rojas-Rueda D; Alsufyani W; Herbst C; AlBalawi S; Alsukait R; Alomran M
Environ Res; 2021 Jun; 197():111036. PubMed ID: 33775683
[TBL] [Abstract][Full Text] [Related]
17. Hypoglycemia unawareness among insulin-treated diabetic patients in Madinah, Saudi Arabia: prevalence and risk factors.
Surrati AMQ; Alanazi AA; Bukhari SS; Alfadhli EM
Front Endocrinol (Lausanne); 2023; 14():1239524. PubMed ID: 37964960
[TBL] [Abstract][Full Text] [Related]
18. Obesity Burden and Impact of Weight Loss in Saudi Arabia: A Modelling Study.
Alqahtani SA; Al-Omar HA; Alshehri A; Abanumay A; Alabdulkarim H; Alrumaih A; Eldin MS; Schnecke V
Adv Ther; 2023 Mar; 40(3):1114-1128. PubMed ID: 36633732
[TBL] [Abstract][Full Text] [Related]
19. Ten-year cost-consequence analysis of weight loss on obesity-related outcomes in privately insured adults with obesity in Saudi Arabia.
Al-Omar HA; Aljehani N; Alshehri A; Al-Khenizan A; Al-Shammari F; Abanumay A; Schnecke V; Carapinha JL; Alqhatani SA
J Med Econ; 2023; 26(1):802-810. PubMed ID: 37272736
[TBL] [Abstract][Full Text] [Related]
20. Projected impact of population aging on non-communicable disease burden and costs in the Kingdom of Saudi Arabia, 2020-2030.
Boettiger DC; Lin TK; Almansour M; Hamza MM; Alsukait R; Herbst CH; Altheyab N; Afghani A; Kattan F
BMC Health Serv Res; 2023 Dec; 23(1):1381. PubMed ID: 38066590
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
